Search the Newsreel

Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating

Barclays has increased its price target for AbbVie (ABBV) to $300 from $275, while reiterating an Overweight rating on the stock. The adjustment reflects an updated outlook from the analytical firm regarding the pharmaceutical company's future performance. AbbVie specializes in therapeutic drug research and …

Goldman Sachs uncovers key AbbVie stock signals before earnings

New Century Logistics (BVI) Limited Revenue Breakdown – NASDAQ:NCEW

Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter

Sarepta Therapeutics has appointed Michael Severino, former vice chairman at AbbVie and CEO of Tessera Therapeutics, as its new chief executive, effective Tuesday. Severino replaces Doug Ingram, who is retiring due to family health issues. Severino will face the challenge of navigating commercial realities …

Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO

Sarepta Therapeutics has appointed Michael Severino, an executive with experience at AbbVie and Amgen and most recently Tessera Therapeutics, as its new CEO, effective July 28. Severino faces the challenge of turning around Sarepta's fortunes, as the company has lost significant market value over …

Sarepta names former AbbVie R&D exec Michael Severino as next CEO

Sarepta Therapeutics has appointed Michael Severino, formerly of Tessera Therapeutics and AbbVie, as its new CEO, succeeding Doug Ingram. Severino takes the helm at a critical juncture as Sarepta awaits two key FDA decisions for its Duchenne muscular dystrophy drugs, Amondys 45 and Vyondys …

AbbVie stock hits all-time high of 261.71 USD

AbbVie Inc. (ABBV) stock has reached a new all-time high of $261.71, reflecting a 40.53% total return over the past year. Despite being considered slightly overvalued by InvestingPro analysis, the company demonstrates strong financial health with 9.5% revenue growth. Upcoming earnings on July 31st …

Is AbbVie Stock a Buy After Its $10.9 Billion Apogee Bet

AbbVie (ABBV) recently acquired Apogee Therapeutics for $10.9 billion, a move that is expected to dilute adjusted EPS until 2032 but aims for a "mega blockbuster" drug, zumilokibart, targeting over $10 billion in peak sales. Despite the near-term dilution, AbbVie stock has largely recovered …

Sarepta names former Abbvie president as CEO as Ingram retires

Sarepta Therapeutics has appointed Michael Severino, former Tessera Therapeutics CEO and a longtime AbbVie executive, as its new chief executive, effective July 28. Severino will succeed Doug Ingram, who is stepping down after leading Sarepta since 2017 but will remain in an advisory role …

New Century Logistics (BVI) Ltd (NCEW) Cash Flow

This article provides an overview of New Century Logistics (BVI) Ltd's (NCEW) cash flow statements, including operating, investing, and financing cash flows, along with definitions for each. It highlights key financial figures for the company, such as a -3.42M operating cash flow in fiscal …

How Abbvie Inc. (ABBV) Affects Rotational Strategy Timing

This article from Stock Traders Daily analyzes Abbvie Inc. (ABBV) and its impact on rotational strategy timing. It highlights a neutral sentiment for ABBV across all horizons, suggesting a wait-and-see approach, and identifies no resistance levels above the current price, indicating potential upside. The …

New Century Logistics (BVI) Ltd (NCEW) Income Statement

This article provides an income statement for New Century Logistics (BVI) Ltd (NCEW) through TradingKey.com, offering both quarterly and annual financial data. It explains how to interpret the income statement, defines key metrics like YOY, and presents NCEW's revenue, net income, and operating profit …

Bureau Veritas SA (ENXTPA:BVI) übernahm LotusWorks Ltd. zu einem Enterprise Value von rund 380 Mio. EUR.

New Century Logistics (BVI) Ltd (NCEW) Valuation: PE, PB & Fair Value Analysis

This article provides an overview of New Century Logistics (BVI) Ltd (NCEW), including its stock price, market capitalization, and P/E TTM ratio. It notes the stock closed at $17.190 with a 3.97% decrease on July 24, and had a pre-market value of $0.000 on …

New Century Logistics (BVI) Ltd (NCEW) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of New Century Logistics (BVI) Ltd (NCEW), detailing various technical indicators and moving averages. It summarizes the buy, sell, and neutral signals for indicators like MACD, RSI, and CCI, as well as different moving averages. The analysis focuses …

New Century Logistics (BVI) Ltd

This article provides a detailed revenue breakdown for New Century Logistics (BVI) Ltd (NCEW), presenting financial data for recent fiscal years. The primary revenue source is air freight forwarding services, accounting for over 95% of the company's income. Other services and ocean freight forwarding …

New Century Logistics (BVI) Ltd (NCEW) Institutional Confidence

The article provides a brief overview of New Century Logistics (BVI) Ltd (NCEW), including its stock performance, market capitalization, and P/E ratio. As of the close on July 24, the stock was trading at $17.190, down 3.97%. The page is from TradingKey, a platform …

New Century Logistics (BVI) Ltd (NCEW) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article from TradingKey provides an overview of the dividend and stock split history for New Century Logistics (BVI) Ltd (NCEW). It notes that no dividends have been distributed in the past five years and highlights a planned 8-to-1 merger stock split scheduled for …

NCEW|New Century Logistics (BVI) Ltd|Price:17.190|Chg%:-0.710

This article provides an overview of New Century Logistics (BVI) Ltd (NCEW), detailing its business operations in air and ocean freight forwarding, warehousing, and project cargo services. It includes key financial information such as its market capitalization and P/E ratio, and lists the company's …

New Century Logistics (BVI) Ltd (NCEW) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for New Century Logistics (BVI) Ltd (NCEW), focusing on volatility, financial risk, and investment risk. It details various metrics such as maximum drawdown, realized volatility, Sharpe Ratio, and daily return/loss over different periods. The data indicates significant volatility …

AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback

AbbVie (ABBV) may be 3% undervalued despite a recent setback in the Phase 3 EPCORE DLBCL-1 trial for its drug epcoritamab. The company's diverse pipeline and strong cash generation suggest potential for future growth, with a fair value estimated at $266.89 against a last …

AbbVie stock trades steadily as Humira erosion meets Skyrizi and Rinvoq growth

AbbVie Inc. is managing a transition as its blockbuster drug Humira faces declining sales due to biosimilar competition. The company is actively offsetting this revenue loss with the strong growth of newer immunology drugs, Skyrizi and Rinvoq, which are showing double-digit percentage growth. Investors …

Should You Pay Attention To AbbVie Stock's Momentum?

The article poses a question about whether investors should pay attention to AbbVie stock's momentum. However, the provided content is largely navigational, legal disclaimers, and technical limitations of an interactive model, without any actual article text or financial analysis regarding AbbVie. It does not …

AbbVie stock may move 4.2% on July 31 earnings report

AbbVie Inc. (NYSE:ABBV) stock is projected to move by 4.2% based on options data ahead of its July 31 earnings release. Historically, the stock's actual movement has often exceeded the implied move from options. The article details past earnings announcement performances, noting instances where …

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbbVie (ABBV) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended June 2026, with results anticipated on July 31. The consensus EPS estimate is $3.66 per share (+23.2% year-over-year) and revenues are projected at $16.81 billion (+9%). …

CNBC ‘Final Trades’: Netflix, AbbVie, Cerebras Systems - Netflix (NASDAQ:NFLX), CrowdStrike Holdings (NAS

This article summarizes the "Final Trades" segment on CNBC, highlighting stock picks from various financial experts. Recommendations include AbbVie (ABBV) with a raised price target, Transocean (RIG) ahead of earnings, Cerebras Systems (CBRS) due to a new cybersecurity partnership with CrowdStrike (CRWD), and Netflix …

ABBV|AbbVie Inc|Price:256.910|Chg%:+3.610

AbbVie Inc. (ABBV) shows stable fundamentals and high growth potential, with its valuation considered fairly valued within the Pharmaceuticals industry. The stock is a high dividend payer and exhibits high institutional ownership. While the stock price is expected to trend upwards in the medium …

Genmab, AbbVie Clarify Epcoritamab Phase 3 Trial Missed Primary Endpoint

Genmab and AbbVie issued a clarification regarding their Phase 3 EPCORE DLBCL-1 trial, stating that overall survival was the sole U.S. primary endpoint and it was not met. This clarification was deemed necessary due to interpretive ambiguity in earlier disclosures, highlighting the complexities of …

Genmab, AbbVie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial

Genmab and AbbVie announced that their lymphoma drug, epcoritamab, did not meet the primary endpoint in a Phase 3 clinical trial. The trial aimed to evaluate the drug's efficacy in patients with diffuse large B-cell lymphoma (DLBCL). This outcome is a setback for the …

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie clarified that overall survival (OS) was the sole U.S. primary endpoint for the Phase 3 EPCORE DLBCL-1 trial, which unfortunately did not meet this endpoint, indicating no statistically significant improvement in OS. The study evaluated epcoritamab in adults with relapsed or …

Epcoritamab U.S. Lymphoma Trial Does Not Meet Survival Endpoint

Genmab and AbbVie announced that their Phase 3 EPCORE® DLBCL-1 trial, evaluating epcoritamab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival in the U.S. market. While epcoritamab is already approved under accelerated pathways for similar conditions, …

AbbVie: Bright Future, But Already Priced In (NYSE:ABBV)

AbbVie Inc. is rated a 'Hold' due to its slight overvaluation and high debt levels, despite strong Q1/26 revenue and free cash flow growth. The company's growth is largely driven by Skyrizi and Rinvoq, with pipeline diversification coming from Neuroscience and the Apogee Therapeutics …

AbbVie Inc. stock underperforms Wednesday when compared to competitors

AbbVie Inc. (ABBV) shares fell 1.09% on Wednesday, closing at $253.30, and underperformed the broader market, with both the S&P 500 and Dow Jones Industrial Average also seeing slight declines. The stock is currently 3.19% below its 52-week high reached earlier in July.

Total equity of AbbVie, Inc. – BCS:ABBV0

This article provides the total equity information for AbbVie, Inc. (BCS:ABBV0) from the Santiago Stock Exchange, accessed via TradingView. It indicates that the market was closed at the time of viewing and no trades were recorded. The content is primarily a data page with …

AbbVie Sues Galderma Over Patented Dermal Filler Syringe Designs

AbbVie Inc. and its Allergan Inc. unit have filed a patent infringement lawsuit against Galderma Group AG and Galderma SA. The lawsuit alleges that Galderma created dermal filler syringes for its Restylane product with a design similar to AbbVie's Juvéderm syringes, infringing on several …

Will AbbVie's Oncology Franchise Remain Under Pressure in Q2?

AbbVie's oncology franchise is facing continued pressure, primarily due to declining Imbruvica sales, despite growth from newer therapies. The Zacks Consensus Estimate for Q2 oncology revenues suggests a slight decline from the previous year. The company's stock has outperformed the industry year-to-date, and it …